AstraZeneca stock slips as Trixeo wins EU asthma approval

Published on 09/23/2026 at 12:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock traded at GBP 126.20 on September 23, 2026, down 0.4 percent in London. Trixeo gained EU asthma approval.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca stock traded at GBP 126.20 in London on September 23, 2026, down 0.4 percent after the European Union approved Trixeo for asthma treatment. The approval gives the respiratory portfolio a fresh commercial milestone.

Trixeo adds a respiratory milestone

According to James Sharp on September 23, 2026, Trixeo received European Union approval for asthma, extending AstraZeneca's respiratory and immunology offering beyond its established chronic obstructive pulmonary disease use.

The market reaction was measured: Zonebourse reported a London price of 12,620 pence and a 0.4 percent decline on September 23, 2026. That contrast matters because a regulatory win does not automatically translate into same-day share-price gains.

Valuation stays above yearly low

Market data from September 23, 2026 put AstraZeneca's 52-week high at GBP 157.30, reached on February 19, 2026, while the 52-week low was GBP 107.84 on September 27, 2025. The quoted GBP 126.20 level was therefore GBP 18.36 below the yearly high and GBP 18.36 above the yearly low.

For US-listed ADR investors, MarketBeat reported a market capitalization of USD 261.00 billion and a 52-week range of USD 145.79 to USD 212.71 on September 23, 2026. The same report listed 14 Buy ratings, three Hold ratings and one Sell rating, producing a Moderate Buy consensus with a USD 206.67 price target, but those figures refer to the NYSE ADR rather than the London reference quote.

London price remains the reference

AstraZeneca stock closed at GBP 124.90 on September 21, 2026, after a 0.08 percent decline, with 466,890 shares traded and a session range of GBP 123.64 to GBP 124.90, according to the dated market report. The September 23 London quote at GBP 126.20 provides the latest trading snapshot used here.

In the near term, the Trixeo approval supplies a concrete respiratory catalyst, while the 0.4 percent London decline shows that investors are still weighing the commercial impact against the company's valuation and broader pharmaceutical-sector conditions.